Last reviewed · How we verify
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of TQH2722 Injection in Subjects With Moderate to Severe Atopic Dermatitis
This phase II clinical trials is multicenter, randomized, double-blind, placebo-controlled to assess the effectiveness and safety of TQH2722 injection in the treatment of subjects with moderate to severe atopic dermatitis.
Details
| Lead sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | UNKNOWN |
| Enrolment | 160 |
| Start date | 2023-06-19 |
| Completion | 2024-03 |
Conditions
- Atopic Dermatitis
Interventions
- TQH2722 injection 300mg-150mg
- TQH2722 injection 600mg-300mg
- TQH2722 injection 900mg-450mg
- TQH2722 injection matching Placebo
Primary outcomes
- Eczema area and severity (EASI)-75 (≥75% improvement from baseline). — Up to 16 weeks.
Proportion of participants with eczema area and severity (EASI)-75 (≥75% improvement from baseline) at week 16.
Countries
China